GlassScriptPhysician profile
Cheyenne Hardy
NPI 1902535180
$9,670.25
in general payments reported to CMS, 2019-2025
61 companies · $3,728 in 2025
The $3,728 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,248 · 2024: $3,694 · 2025: $3,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,300 · Education: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,299.54 |
| Education | $1,370.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $965.75 | 2023-2025 | |
| Astellas Pharma US INC | $792.66 | 2023-2025 | Xospata, Xtandi, Cresemba |
| Astrazeneca Pharmaceuticals LP | $738.97 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| Janssen Biotech, INC. | $598.75 | 2023-2025 | Erleada, Akeega, Tecvayli |
| Merck Sharp & Dohme LLC | $526.50 | 2023-2025 | Keytruda, Reblozyl, Lynparza |
| Seagen INC. | $501.32 | 2023-2025 | Adcetris, Tukysa |
| Celgene Corporation | $461.39 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Incyte Corporation | $374.65 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Pfizer INC. | $366.06 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $309.53 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $307.56 | 2023-2025 | Opdualag, Opdivo |
| Glaxosmithkline, LLC. | $278.33 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $273.17 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.68 | 2023-2025 | Fruzaqla, Ninlaro |
| Dendreon Pharmaceuticals LLC | $189.68 | 2024 | Provenge |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $180.92 | 2025 | Givlaari, Oxlumo |
| Genzyme Corporation | $158.66 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $146.66 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Beigene USA, INC. | $136.05 | 2024-2025 | Brukinsa, Tevimbra |
| Beone Medicines USA, INC. | $126.42 | 2025 | Brukinsa, Tevimbra |
| Array Biopharma INC | $118.65 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Lilly USA, LLC | $112.59 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $109.89 | 2024-2025 | Libtayo |
| Genmab U.S., INC. | $107.23 | 2024-2025 | Epkinly |
| Exelixis INC. | $105.02 | 2023-2025 | Cabometyx |
| Acrotech Biopharma INC. | $92.80 | 2023-2025 | Beleodaq, Ryzneuta |
| Pharmacyclics LLC, An Abbvie Company | $85.83 | 2023 | Imbruvica |
| Blueprint Medicines Corporation | $83.25 | 2024-2025 | Ayvakit |
| Stemline Therapeutics INC. | $82.00 | 2025 | Orserdu |
| Spectrum Pharmaceuticals INC. | $77.03 | 2023-2025 | Rolvedon |
| Tersera Therapeutics LLC | $68.76 | 2023-2024 | Zoladex |
| Amgen INC. | $63.56 | 2023 | Kyprolis, Blincyto, Nplate |
| Tempus Ai, INC | $63.55 | 2024 | |
| Aveo Pharmaceuticals, INC. | $61.98 | 2023-2025 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $59.52 | 2024 | |
| Adc Therapeutics America, INC. | $55.25 | 2025 | |
| Deciphera Pharmaceuticals INC. | $47.52 | 2024 | Qinlock |
| Daiichi Sankyo INC. | $44.20 | 2023-2025 | Enhertu, Vanflyta |
| Gilead Sciences, INC. | $43.37 | 2024-2025 | Trodelvy |
| Iovance Biotherapeutics, INC. | $41.03 | 2025 | Amtagvi |
| Sobi, INC | $39.33 | 2024 | |
| Apellis Pharmaceuticals, INC. | $39.05 | 2023-2024 | Empaveli |
| Servier Pharmaceuticals LLC | $37.96 | 2023-2024 | |
| Syndax Pharmaceuticals, INC. | $37.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.21 | 2025 | |
| Legend Biotech USA INC. | $31.89 | 2025 | Carvykti |
| Taiho Oncology, INC. | $31.14 | 2024 | |
| Coherus Oncology, INC. | $29.45 | 2024 | |
| Puma Biotechnology, INC. | $26.53 | 2023 | |
| Genentech USA, INC. | $23.20 | 2024 | Itovebi |
| Myriad Genetic Laboratories, INC. | $22.51 | 2024 | Myrisk |
| Pharmaand Gmbh | $21.61 | 2025 | Rubraca |
| Mirati Therapeutics, INC. | $19.95 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $19.79 | 2024 | Monoferric |
| Morphosys, US INC. | $19.62 | 2023 | Monjuvi |
| Boston Scientific Corporation | $17.71 | 2025 | Spaceoar Vue System - 10ml |
| Recordati_rare_diseases_inc. | $17.49 | 2023 | Sylvant |
| Azurity Pharmaceuticals, INC. | $16.40 | 2024 | Vivimusta |
| Pharmaessentia USA Corporation | $15.41 | 2025 | Besremi |
| Geron Corporation | $14.00 | 2025 | Rytelo |
| Janssen Scientific Affairs, LLC | $4.85 | 2025 | Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheyenne Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.